Julia Kovacs, MD
Internal Medicine · Houston, TXNPI 1366527798
Payments from drug & device makers
Across 218 payments — averaging $19.50 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$568
- Gilead$535
- Novo Nordisk$441
- AstraZeneca$417
- AbbVie$394
- Viiv Healthcare Company$385
- plus $2K from 28 others
What the payments were for
- Food & beverage$4,251100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Lilly USA, LLC | 27 | $568 |
| Gilead | 29 | $535 |
| Novo Nordisk | 25 | $441 |
| AstraZeneca | 23 | $417 |
| AbbVie | 21 | $394 |
| Viiv Healthcare Company | 16 | $385 |
| Amgen | 11 | $166 |
| Pfizer | 6 | $142 |
| GSK | 6 | $137 |
| Boehringer Ingelheim | 5 | $96 |
| Dexcom, Inc. | 4 | $95 |
| Exact Sciences | 4 | $76 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 5 | $71 |
| Biosense Webster, Inc. | 2 | $65 |
| Abbott | 3 | $63 |
| Idorsia Pharmaceuticals US Inc | 3 | $60 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $58 |
| Sanofi-aventis U.S. LLC | 2 | $43 |
| Azurity Pharmaceuticals, Inc. | 2 | $42 |
| Merck | 3 | $40 |
| Astellas Pharma US Inc | 2 | $40 |
| Bayer | 2 | $38 |
| Antares Pharma, Inc. | 2 | $36 |
| Baxter Healthcare | 1 | $36 |
| Tolmar, Inc. | 2 | $34 |
| Esperion Therapeutics, Inc. | 2 | $30 |
| Otsuka America Pharmaceutical, Inc. | 1 | $22 |
| Sanofi Pasteur Inc. | 1 | $22 |
| Amarin Pharma, Inc. | 1 | $20 |
| Edwards Lifesciences | 1 | $18 |
| Johnson & Johnson | 1 | $16 |
| Halozyme Inc | 1 | $16 |
| Genentech USA, Inc. | 1 | $15 |
| Nestle Healthcare Nutrition Inc. | 1 | $13 |
How this compares
$4,251 in reported general payments places this provider in the 85th percentile of 7,675 internal medicine providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 118 | $158,257 |
| BiktarvyBictegrav/Emtricit/Tenofov Ala | 24 | $108,936 |
| OzempicSemaglutide | 43 | $65,084 |
| FarxigaDapagliflozin Propanediol | 46 | $53,670 |
| GenvoyaElviteg/Cob/Emtri/Tenof Alafen | 12 | $46,467 |
| TriumeqAbacavir/Dolutegravir/Lamivudi | 14 | $46,404 |
| JardianceEmpagliflozin | 32 | $43,089 |
| JanuviaSitagliptin Phosphate | 23 | $35,455 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 36 | $34,162 |
| EliquisApixaban | 13 | $18,139 |
| LinzessLinaclotide | 16 | $13,662 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 22 | $12,297 |
| MyrbetriqMirabegron | 12 | $7,159 |
| InvokanaCanagliflozin | 12 | $6,991 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 25 | $5,446 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro | $568 | $158,257118 claims |
| GileadBiktarvy, Genvoya | $535 | $155,40336 claims |
| Novo NordiskOzempic | $441 | $65,08443 claims |
| AstraZenecaFarxiga, Symbicort | $417 | $58,57057 claims |
| GSKTrelegy Ellipta, Anoro Ellipta | $137 | $46,45958 claims |
| Viiv Healthcare CompanyTriumeq | $385 | $46,40414 claims |
| Boehringer IngelheimJardiance | $96 | $43,08932 claims |
| MerckJanuvia, Janumet Xr | $40 | $38,90635 claims |
| PfizerEliquis | $142 | $18,13913 claims |
| AbbVieLinzess, Synthroid | $394 | $16,04675 claims |
| Astellas Pharma US IncMyrbetriq | $40 | $7,15912 claims |
| Johnson & JohnsonInvokana | $16 | $6,99112 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 7,675 internal medicine providers in Texas.
Other internal medicine in Houston
- Jan BurgerHouston$47.3M
- Nitin JainHouston$33.2M
- Aung NaingHouston$30.6M
- Preetesh JainHouston$19.5M
- Paolo StratiHouston$19.2M
- Nicholas ShortHouston$17.6M
- Isabella GlitzaHouston$14.8M
- Murtaza MussajiHouston$13.1M
- Hussein TawbiHouston$12.6M
- Hans LeeHouston$11.7M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.